Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid 1Leukemia 1

Interventions

Cytarabine 14fludarabine 13venetoclax 11Imatinib Mesylate 9Cyclophosphamide 8Azacitidine 8fludarabine phosphate 7Busulfan 7Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6thymoglobulin 4ponatinib 4nilotinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4asciminib 3aldesleukin 3Melphalan 3Interleukin-2 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Decitabine 3Bone Marrow Transplantation 3Antilymphocyte Serum 3zosuquidar trihydrochloride 2gilteritinib 2enasidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × CC 401 × Other hematologic neoplasm × Clear all
NCT00126893 2007-05-15

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Celgene

Phase 1 Terminated
36 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡